Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial-Reference-Cited by-同舟云学术

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial

Published:2018-03 Issue:3 Volume:5 Page:e117-e126
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Kantarjian Hagop M,Fenaux Pierre,Sekeres Mikkael A,Szer Jeffrey,Platzbecker Uwe,Kuendgen Andrea,Gaidano Gianluca,Wiktor-Jedrzejczak Wieslaw,Carpenter Nancy,Mehta Bhakti,Franklin Janet,Giagounidis Aristoteles

Publisher

Elsevier BV

Subject

Hematology

Reference24 articles.

1. A prognostic score for patients with lower risk myelodysplastic syndrome;Garcia-Manero;Leukemia,2008

2. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome;Gonzalez-Porras;Cancer,2011

3. The incidence and impact of thrombocytopenia in myelodysplastic syndromes;Kantarjian;Cancer,2007

4. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System;Kantarjian;Cancer,2008

5. Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study;Manoharan;Int J Hematol,2002

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08

2. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08

3. Thrombopoietin Agonism to Promote Platelet Engraftment Following Hematopoietic Stem Cell Transplantation: Promising, but Not Ready for Primetime;Transplantation and Cellular Therapy;2024-05

4. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities;Current Hematologic Malignancy Reports;2024-04-18

5. Novel Perspectives on Thrombopoietin Receptor Agonists Applications;Hämostaseologie;2024-03-18